Screener
Celldex Therapeutics CLDX Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingent liabilities | ||
| Stockholders’ equity: | ||
| Convertible preferred stock, $.01 par value; 3,000,000 shares authorized; no shares issued and outstanding at June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $.001 par value; 297,000,000 shares authorized; 78,500,173 and 66,549,442 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 79 | 67 |
| Additional paid-in capital | 2,679,356 | 2,337,453 |
| Accumulated other comprehensive income | 1,298 | 3,626 |
| Accumulated deficit | (1,966,169) | (1,813,981) |
| Total stockholders’ equity | 714,564 | 527,165 |
Item 1. Unaudited Financial Statements
FAQ
- What is Celldex Therapeutics's common stock?
- Celldex Therapeutics (CLDX) reported common stock of $79K in Q2 2026.
- How has Celldex Therapeutics's common stock changed year-over-year?
- Celldex Therapeutics's common stock increased by 19.7% year-over-year, from $66K to $79K.
- What is the long-term trend for Celldex Therapeutics's common stock?
- Over 5 years (2020 to 2025), Celldex Therapeutics's common stock has grown at a 10.9% compound annual growth rate (CAGR), from $40K to $67K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Celldex Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude